SLPMEDIUM SIGNALFINANCIAL10-K

SLP significantly deleveraged its balance sheet while maintaining steady revenue growth and improving operational cash flow generation.

The company's substantial debt reduction and decreased total liabilities suggest either debt paydown or potential asset divestiture, creating a cleaner capital structure. The improved operating cash flow paired with modest revenue growth indicates strengthening operational efficiency, though the decline in total assets and stockholders' equity warrants closer examination of the underlying transactions.

Comparing 2025-12-01 vs 2024-10-30View on EDGAR →
FINANCIAL ANALYSIS

SLP demonstrated solid financial health improvements with revenue growing 10.5% to $59.6M and operating cash flow expanding notably to $18.1M. The balance sheet underwent significant restructuring, with total liabilities nearly halving and debt declining substantially, while current assets increased 31% providing enhanced liquidity. Despite total assets and stockholders' equity declining by approximately one-third, the overall financial picture suggests disciplined capital management and improved operational efficiency.

FINANCIAL STATEMENT CHANGES
Total Liabilities
Balance Sheet
-49.8%
$14.2M$7.1M

Liabilities reduced 49.8% — deleveraging improves balance sheet strength and financial flexibility.

Current Liabilities
Balance Sheet
-44.3%
$12.1M$6.7M

Current liabilities reduced — improved short-term financial position and working capital health.

Total Debt
Balance Sheet
-41.9%
$5.7M$3.3M

Debt reduced 41.9% — deleveraging strengthens balance sheet and reduces financial risk.

Operating Cash Flow
Cash Flow
+36.1%
$13.3M$18.1M

Operating cash flow surged 36.1% — exceptional cash generation, highest quality earnings signal.

Total Assets
Balance Sheet
-32.9%
$196.6M$131.9M

Total assets contracted 32.9% — asset sales, write-downs, or balance sheet optimization underway.

Stockholders Equity
Balance Sheet
-31.6%
$182.4M$124.8M

Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.

Current Assets
Balance Sheet
+31%
$39.3M$51.5M

Current assets grew 31% — improving short-term liquidity or inventory/receivables build.

Capital Expenditure
Cash Flow
+26%
$566K$713K

Capex increased 26% — ongoing investment in capacity or infrastructure for future growth.

R&D Expense
P&L
+19.6%
$5.8M$6.9M

R&D investment increased 19.6% — signals commitment to future product development, though near-term margin impact.

Revenue
P&L
+10.5%
$53.9M$59.6M

Revenue growing 10.5% — solid top-line momentum, watch margins for quality of growth.

LANGUAGE CHANGES
NEW — 2025-12-01
PRIOR — 2024-10-30
ADDED
As of November 14, 2025, 20,144,564 shares of the registrant s common stock were outstanding.
The Company is a global leader and premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery and development, clinical trial operations, and commercialization.
The Company supports its clients across the drug development lifecycle from early discovery through all phases of clinical research and development ( R D ), including clinical operations, to product commercialization.
The Company serves clients as a strategic partner throughout the entire drug development lifecycle, offering solutions that integrate scientific software platforms, artificial intelligence-augmented insights, and expert consulting.
This optimizes efficiency, costs, and time-to-market for our clients, thereby enhancing our competitive position.
+7 more — sign up free →
REMOVED
As of October 18, 2024, 20,067,184 shares of the registrant s common stock were outstanding.
We are a global leader and premier provider in the biopharma sector, offering advanced software and consulting services that enhance drug discovery, development, research, clinical trial operations, regulatory submissions, and commercialization.
With the June 2024 acquisition of Pro-ficiency Holdings, Inc.
and its subsidiaries (collectively, Pro-ficiency ), the Company extended its reach across the drug development value chain from the initial protocol stage through all phases of clinical research and development ( R D ) to product commercialization.
Simulations Plus now has a one-of-a-kind platform to serve its clients at every step in the drug development process.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →